Study Number: I10482B
Test Type: TOX
Route: Dosing in Feed
Species/Strain: Rat/Harlan Sprague Dawley

M19: TDAR SRBC: ELISpot
Test Compound: N-Butylbenzenesulfonamide
CAS Number: 3622-84-2

Date Report Requested: 08/19/2022
Time Report Requested: 08:39:16
Lab: Burleson Research Technologies

Study Number: I10482B
Study Gender: Both
PWG Approval Date: See web page for date of PWG Approval
Version: v1.4.2
Stat Version: v2.9.1A
### F1 Males: SRBC

<table>
<thead>
<tr>
<th></th>
<th>0</th>
<th>250</th>
<th>500</th>
<th>1000</th>
<th>15 mg/kg CPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spleen Weight (g)</td>
<td>0.6747 ± 0.0269 (12) *</td>
<td>0.7512 ± 0.0257 (12)</td>
<td>0.6593 ± 0.0266 (12)</td>
<td>0.6167 ± 0.0270 (12)</td>
<td>0.4771 ± 0.0213 (8) **</td>
</tr>
<tr>
<td>Spleen Cells (x10^6)</td>
<td>260.30 ± 15.16 (12) **</td>
<td>275.60 ± 15.90 (12)</td>
<td>216.90 ± 14.49 (12) *</td>
<td>163.15 ± 13.71 (12) **</td>
<td>85.66 ± 8.73 (8) **</td>
</tr>
<tr>
<td>IgM AFC/10^5 Spleen Cells</td>
<td>118.8 ± 29.5 (12)</td>
<td>100.4 ± 45.8 (12)</td>
<td>75.6 ± 23.2 (12)</td>
<td>144.8 ± 45.3 (12)</td>
<td>1.9 ± 0.6 (8) **</td>
</tr>
<tr>
<td>IgM AFC/Spleen (x10^3)</td>
<td>30.92 ± 7.79 (12)</td>
<td>29.87 ± 14.31 (12)</td>
<td>17.47 ± 5.76 (12)</td>
<td>22.52 ± 6.17 (12)</td>
<td>0.18 ± 0.07 (8) **</td>
</tr>
</tbody>
</table>

**Study Number:** I10482B  
**Test Type:** TOX  
**Route:** Dosing in Feed  
**Species/Strain:** Rat/Harlan Sprague Dawley  
**Test Compound:** N-Butylbenzenesulfonamide  
**CAS Number:** 3622-84-2  
**Date Report Requested:** 08/19/2022  
**Time Report Requested:** 08:39:16  
**Lab:** Burleson Research Technologies
<table>
<thead>
<tr>
<th></th>
<th>0</th>
<th>250</th>
<th>500</th>
<th>1000</th>
<th>15 mg/kg CPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spleen Weight (g)</td>
<td>0.5912 ± 0.0186 (12) **</td>
<td>0.6061 ± 0.0226 (11)</td>
<td>0.5509 ± 0.0249 (12)</td>
<td>0.5295 ± 0.0159 (11) *</td>
<td>0.4344 ± 0.0137 (8) **</td>
</tr>
<tr>
<td>Spleen Cells (x10^6)</td>
<td>254.30 ± 12.00 (12) *</td>
<td>272.56 ± 32.40 (11)</td>
<td>245.45 ± 15.82 (12)</td>
<td>195.27 ± 14.23 (11) *</td>
<td>98.55 ± 7.26 (8) **</td>
</tr>
<tr>
<td>IgM AFC/10^6 Spleen Cells</td>
<td>212.3 ± 46.3 (12)</td>
<td>210.7 ± 75.8 (11)</td>
<td>178.5 ± 33.0 (12)</td>
<td>237.3 ± 79.7 (11)</td>
<td>6.6 ± 3.4 (8) **</td>
</tr>
<tr>
<td>IgM AFC/Spleen (x10^3)</td>
<td>52.20 ± 11.17 (12)</td>
<td>56.78 ± 20.16 (11)</td>
<td>43.49 ± 8.13 (12)</td>
<td>49.73 ± 17.86 (11)</td>
<td>0.64 ± 0.32 (8) **</td>
</tr>
</tbody>
</table>
The ELISpot assay was conducted on the same set of animals as the AFC assay. Data for spleen weight and spleen cell count reported here are also included on the M07 report.

Data are displayed as mean ± SEM (N) unless otherwise noted.

TDAR - T-Dependent Antibody Response; SRBC - Sheep Red Blood Cells; AFC - Antibody-Forming Cells; IgM - Immunoglobulin M

Statistical analysis was performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Statistical analysis for the positive control group compared to the vehicle control group was performed using the Kruskal-Wallis test.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

* Statistically significant at P <= 0.05

** Statistically significant at P <= 0.01

CPS = Cyclophosphamide

** END OF REPORT **